Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the combination of gemtuzumab ozogamicin,
mitoxantrone and etoposide as second line therapy in patients with acute myeloid leukemia.